Improving care of chronic heart failure: Advances from drugs to devices
Randall C. Starling, MD, MPH
Section of Heart Failure and Cardiac Transplant Medicine, Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, Cleveland Clinic
Address: Randall C. Starling, MD, MPH, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
The author has indicated that he has received grant or research support from Acorn Cardiovascular corporation, and is a consultant for Novartis.
This paper discusses therapies that are experimental or not approved by the US Food and Drug Administration for the use under discussion.
Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the authors but are not peer-reviewed.
ABSTRACTThe right combination of drugs and surgical treatment can improve systolic function and prevent, attenuate, or reverse heart failure. Patient education and disease management programs can reduce hospitalizations. Optimal treatment for each patient is guided by a thorough evaluation and use of functional classification and disease staging systems.